# Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

> **NCT03880474** · PHASE2 · TERMINATED · sponsor: **Barinthus Biotherapeutics** · enrollment: 2364 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** MVA-NP+M1
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT03880474
- **Lead sponsor:** Barinthus Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-18
- **Primary completion:** 2019-10-15
- **Final completion:** 2020-01-21
- **Target enrollment:** 2364 (ACTUAL)
- **Why stopped:** The trial is being stopped for futility. Season 2 cancelled.
- **Last updated:** 2021-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03880474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03880474, "Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03880474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*